---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-24-000116"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T03:46:10.516444+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q1: INGREZZA sales $506M (+23% YoY); GAAP EPS $0.42, non-GAAP EPS $1.20

## Summary
- INGREZZA net product sales $506M in Q1 2024 vs $411M in Q1 2023, up 23% year-over-year.
- GAAP net income $43.4M ($0.42 diluted EPS) vs net loss $76.6M ($0.79 loss) in Q1 2023.
- Non-GAAP net income $124.8M ($1.20 diluted EPS) vs net loss $49.5M ($0.51 loss) a year ago.
- Total revenues $515.3M (+23% YoY); cash & equivalents $1.91B at quarter end.
- FDA approved INGREZZA SPRINKLE; NDAs submitted for crinecerfont in congenital adrenal hyperplasia.

## SEC filing metadata
- accession: 0000914475-24-000116
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447524000116/0000914475-24-000116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447524000116/nbix-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-24-000116
- JSON: https://secwatch.observer/filing/0000914475-24-000116.json
- Plain text: https://secwatch.observer/filing/0000914475-24-000116.txt

## Key facts
- Earnings Releases
  NEUROCRINE BIOSCIENCES INC reported the first quarter ended March 31, 2024 results: revenue $515.3 million, net income $43.4 million, EPS $0.42. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $515.3 million
  - Net income: $43.4 million
  - EPS: $0.42
  - Guidance: reaffirmed
  - Result: reported results
  source text: Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000091447524000116/0000914475-24-000116-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.